EPO and myelodysplastic syndrome: In a randomized phase 3 study, 147 low‐risk MDS patients with hemoglobin (Hb) level of ≤10 g/dL, EPO level of ≤500 mU/mL, and low transfusion load were randomized to receive ESA or placebo.76